SU-E-J-140: Availability of Using Diaphragm Matching in Stereotactic Body Radiotherapy (SBRT) at the Time in Breath-Holding SBRT for Liver Cancer

2014 ◽  
Vol 41 (6Part8) ◽  
pp. 188-188
Author(s):  
D Kawahara ◽  
S Ozawa ◽  
T. Nakashima ◽  
M. Aita ◽  
S. Tsuda ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Breath Holding

scholarly journals Interfractional diaphragm changes during breath-holding in stereotactic body radiotherapy for liver cancer

2018 ◽  
Vol 23 (2) ◽  
pp. 84-90 ◽  
Author(s):  
Daisuke Kawahara ◽  
Shuichi Ozawa ◽  
Takeo Nakashima ◽  
Shintaro Tsuda ◽  
Yusuke Ochi ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Breath Holding

scholarly journals Availability of Using Diaphragm Matching in Stereotactic Body Radiotherapy (SBRT) at the Time in Breath-holding SBRT for Liver Cancer

2014 ◽  
Vol 70 (1) ◽  
pp. 51-56 ◽  
Author(s):  
Daisuke Kawahara ◽  
Syuichi Ozawa ◽  
Takeo Nakashima ◽  
Masamichi Aita ◽  
Shintarou Kawai ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Breath Holding

SU-F-J-136: Impact of Audiovisual Biofeedback On Interfraction Motion Over a Course of Liver Cancer Stereotactic Body Radiotherapy

2016 ◽  
Vol 43 (6Part10) ◽  
pp. 3438-3438
Author(s):  
S Pollock ◽  
R Tse ◽  
D Martin ◽  
L McLean ◽  
M Pham ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Interfraction Motion

scholarly journals Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer

2017 ◽  
Vol 6 (6) ◽  
pp. 911-916
Author(s):  
Ya-Zheng Dang ◽  
Xin Li ◽  
Shi-Gao Huang ◽  
Wan-Ling Lu ◽  
Guodong Wang ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Primary Liver Cancer ◽  
Curative Effect

scholarly journals Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy

EBioMedicine ◽  
2020 ◽  
Vol 59 ◽  
pp. 102973
Author(s):  
Sylvia S.W. Ng ◽  
Gun Ho Jang ◽  
Irwin J. Kurland ◽  
Yunping Qiu ◽  
Chandan Guha ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy

scholarly journals Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4–B1: a pilot study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Feiqian Wang ◽  
Kazushi Numata ◽  
Atsuya Takeda ◽  
Katsuaki Ogushi ◽  
Hiroyuki Fukuda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Radiofrequency Ablation ◽  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Large Scale ◽  
White Blood Cells ◽  
Novel Therapy ◽  
One Year ◽  
The One

Abstract Background In clinical practice, many hepatocellular carcinoma (HCC) patients in Barcelona Clinical Liver Cancer (BCLC) stage A4–B1 cannot receive the curative treatments of liver transplantation, resection, and radiofrequency ablation (RFA), which are the recommended options according to liver cancer guidelines. Our aim is to study the feasibility of RFA and stereotactic body radiotherapy (SBRT) as a curative treatment for different multifocal HCCs in BCLC stage A4–B1 patients. Methods From September 2014 to August 2019, 39 multifocal HCC lesions (median diameter: 16.6 mm) from 15 patients (median age: 73 years) were retrospectively selected. Among them, 23 were treated by RFA and the other 16 by SBRT because of predictable insufficiency and/or risk related to RFA performance. The indicators for evaluating this novel therapy were the tumor response, prognosis (recurrence and survival), and adverse effects (deterioration of laboratory test values and severe complications). Results The median follow-up duration was 31.3 months (range: 15.1–71.9 months). The total patients with a one-year complete response, stable disease, or disease progression were 11, 1, and 3, respectively. In total, 8 and 2 patients had confronted intrahepatic or local recurrence, respectively. The one-year progression-free survival rate and local control rate were 80% (12/15 patients) and 97.4% (38/39 lesions), respectively. The median time to progression was 20.1 (2.8–45.1) months. The one- and two-year survival rates were 100 and 88.9%, respectively. In up to five months’ observation, no patient showed severe complications. Seven, four, and two patients had slight changes in their white blood cells, platelet count, or albumin–bilirubin grade, respectively. Conclusions For patients with BCLC stage A4–B1, RFA and SBRT treatment for different multifocal HCCs may be a potential option because of the favorable prognosis and safety. However, before its application in clinical practice, prospective, controlled, large-scale studies are needed to further confirm our conclusions.

scholarly journals Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245076
Author(s):  
Feiqian Wang ◽  
Kazushi Numata ◽  
Atsuya Takeda ◽  
Katsuaki Ogushi ◽  
Hiroyuki Fukuda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Side Effects ◽  
Liver Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Control Group ◽  
Control Groups ◽  
Short Term ◽  
Safety And Efficacy ◽  
And Control

Aim To evaluate the safety and efficacy of the administration of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the short term to the same patients in Barcelona Clinical Liver Cancer (BCLC) stages 0–B1. Methods From April 2014 to June 2019, we retrospectively reviewed BCLC stage 0–B1 patients with fresh hepatocellular carcinoma (HCC) lesions that were repeatedly treated by RFA (control group, n = 72), and by RFA and subsequent SBRT (case group, n = 26). Propensity score matching (PSM) was performed to reduce the selection bias between two groups. Recurrence, survival, Child–Pugh scores and short-term side effects (fever, bleeding, skin change, abdominal pain and fatigue) were recorded and analyzed. Results After PSM, 21 patients remained in each group. Seventeen and 20 patients in the case and control groups experienced recurrence. For these patients, the median times to progression and follow-up were 10.7 and 35.8 months, respectively. After PSM, the 1-year progression-free survival rate in case and control groups were 66.7% and 52.4%, respectively (P = 0.313). The inter-group overall survival (OS) was comparable (3 and 5-year OS rates in case groups were 87.3% and 74.8%, while rates in control groups were 73.7% and 46.3%, respectively; P = 0.090). The short-term side effects were mild, and the incidence showed no inter-group difference. The 1-year rates of the Child–Pugh score deterioration of ≥2 in case and control groups were 23.8% and 33.3% (P > 0.05), respectively. Conclusion The short-term administration of RFA and SBRT to the same BCLC stage 0–B1 patients may be feasible and effective because of their good prognosis and safety.

Sign in / Sign up

Export Citation Format

Share Document